In the present study, we evaluate the serum level of common autoimmunologic markers in women with polycystic ovary syndrome (PCOS) and study their relationship with hormonal parameters. The study was an observational case-control study, done in a Tertiary referral hospital, the study included 50 women with polycystic ovary syndrome and 50 matched control. Serum levels of Antinuclear Antibody (ANA) and anti-double-stranded DNA (dsDNA) were signi icantly higher in polycystic ovary syndrome women compared to control. Also, luteinizing hormone (LH), follicle stimulating hormone (FSH), and LH/FSH ratio were signi icantly higher in polycystic ovary syndrome women compared to control. dsDNA had excellent ability to differentiate PCOS from control (AUC=0.901) while ANA had good discrimination ability (AUC=0.809). There was a signi icant direct relationship between ANA, dsDNA, and TSH with FSH in PCOS women, also a signi icant direct relationship between ANA and TSH with LH, while DsDNA did not correlate with LH. In conclusion, there is a clear relationship between immunological markers (ANA, dsDNA) with polycystic ovary syndrome in various components of the disease, dsDNA offer better ability than ANA as a predictor of PCOS, indicating that dsDNA can be used as a non-invasive diagnostic tool for PCOS.
INTRODUCTION
Polycystic ovarian syndrome (PCOS) affects 5 to 10% of women of childbearing age and is the most common cause of anovulatory infertility in developed countries; it is characterized by the presence of two or three of the following features: Oligoovulation or anovulation, hyperandrogenism, and polycystic ovaries. (NESTLER et al., 1998) .
The irst evidence for antinuclear antibodies arose in 1948 when Hargraves, Richmond, and Morton discovered the LE cell (HARGRAVES et al., 1948) . These abnormal cells, which are found in the bone marrow of persons with systemic lupus erythematosus (SLE), are categorized as polymorph nuclear leukocytes with phagocytized whole nuclei (SHAO and COHEN, 2011) . Subsequently, in 1957, antibodies to dsDNA were the irst autoantibodies to be identi ied in patients with SLE (STOLLAR, 1989) . Antinuclear antibodies are a group of antibodies found against a variety of nuclear antigens have been detected in the serum of patients with autoimmune diseases. An in lammatory response will increase the production of ANA which can be measured and used as a marker for disease activity in sera (DEHAGHANI et al., 2013) .
In autoimmunity, there is a failure in mechanisms responsible for self-tolerance and regulation with overstimulation of immune response against selfcomponents. Also, its characterized by induction of autoreactive cells toward antigens (e.g., antibodies). Autoimmunity had been classi ied as organspeci ic and non-organ speci ic. The in lammatory process, hyperstimulation of immunity, and the process of tissue destruction expose intracellular antigens leads to the production of ANA, which is a hallmark of autoimmune disorders. This marker (i.e., ANA) has been detected in several autoimmune disorders like systemic lupus erythematosus, Sjogren's syndrome, autoimmune hepatitis, dermatomyositis, and polymyositis. Low levels of progesterone in PCOS lead to overstimulates the immune system and causing uncontrolled production of autoantibodies, and it will lead to an autoimmune disorder (MOBEEN et al., 2016) . The current work aimed to evaluate autoimmune markers ANA and dsDNA in women with PCOS and to evaluate the correlation between these autoantibodies with serum FSH, LH, LH/FSH ratio and serum TSH levels in polycystic ovary syndrome. Extensive general, abdominal, and pelvic examinations were performed for all included women.
MATERIALS AND METHODS

Patient selection and study design
Transvaginal ultrasound was performed to evaluate the ovaries and uterus.
The study was approved by the scienti ic council of Gynecology and obstetrics Arabic board , written inform consent obtained from the patients, and this study done in accordance of Helsinki Declaration.
Inclusion criteria
1. Age between 18 to 40 years 2. Con irmed
Exclusion criteria
1. A history of medical treatment, hyperthyroidism, hyperprolactinemia, or chronic hypertension 2. Any hormonal treatment during the previous three months before the study or any medication affecting ANA and dsDNA levels, such as antipsychotics (e.g., chlorpromazine, haloperidol, and clozapine)
3. Drug-induced lupus associated with pyrazinamide or sulfadiazine.
4. Aromatase inhibitors (e.g., letrozole and anastrozole), which increase the incidence of autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Sample collection
Blood samples were obtained in the morning to determine serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroidstimulating hormone (TSH), and serological tests. Serum ANA levels were measured by immunometric enzyme immunoassay against nucleosomes, and ELISA measured IgG class autoantibodies against ds-DNA.
Serum level of ANA was considered to be positive if above or equal to 10 IU/mL for autoimmune disease, while for dsDNA levels below 30 IU/mL considered to be negative, levels between 30 -75 IU/mL considered to be borderline and levels above 75 IU/mL is positive for autoimmune disease.
Statistical analysis
Discrete variables presented using their numbers and percentages; Chi-square test was used to analyze the discrete variables (or Fisher exact test when Chi-square test is not valid; due to low sample size < 20 and if two or more with an expected frequency is less than 5). Two samples t-test was used to analyze the differences in means between two groups (if both follow a normal distribution with no signi icant outlier). Receiver operator curve used to see the validity of different parameters in separating cases with torsion from none torsion and area under the curve, i.e. AUC and its p-value prescribe this validity (if AUC ≥ 0.9 mean excellent test, 0.8 -0.89 means good test, 0.7 -0.79 fair test otherwise unacceptable). Linear regression analysis was performed to assess the relationship between different variables. SPSS 22 (Chicago, IL), MedClac 14.8.1, GraphPad Prism 7.0 software package was used to make the statistical analysis, p-value considered to be signi icant if less than 0.05.
Results
Serum levels of LH, LH/FSH ratio, TSH, ANA, dsDNA was signi icantly higher in PCOS compared to control, while FSH was signi icantly lower in PCOS compared to control, as illustrated in Table 1 . Anti dsDNA had higher validity than ANA for differentiating PCOS (since it has higher AUC), both had similar sensitivity, but dsDNA had higher speci icity than ANA. Since PPV and NPV for dsDNA is 84% indicating it has the similar ability for con irmation and exclusion of PCOS, as illustrated in Table 2 There was a signi icant direct relationship between ANA, dsDNA, and TSH with FSH in PCOS women, also a signi icant direct relationship between ANA and TSH with LH, while DsDNA did not correlate with LH, as illustrated in Table 3 . 
RESULTS AND DISCUSSION
In the current study, two of the most common immunological markers were examined (antinuclear antibodies and double-stranded DNA) both represent the basic markers used in the diagnosis of autoimmune diseases. In this study serum ANA was signi icantly higher in PCOS group compared to control (8.0 ± 2.7 vs. 5.1 ± 2.6 IU/ml respectively), these indings were in agreement with Reimand et al. (REIMAND et al., 2001) in their casecontrol study which includes 108 female cases with various reproductive diseases from this group 20 women had PCOS 6 women had elevated ANA (6/20, 30%) compared to 14 out of 392 (3.6%) of normal age matched control women and this was statistically signi icant, additionaly the currnet study agreed with a recent study in Egypt published in 2015 in which Makled et al. (MAKLED et al., 2015) performed a case control study on 50 PCOS and 50 age-matched control women and found that PCOS women had signi icantly higher ANA titer compared to control (9.0 ± 6.1 vs. 5.4 ± 2.3 U/ml) with 36.0% of PCOS had elevated ANA vs. 6.0% in the control group, on the other hand, the results of this study concerning ANA was in disagreement with He lerFrischmuth et al. (He ler-Frischmuth et al., 2010) , they performed case control study with 109 PCOS against 109 matched control in Austria 2010; which they reported no differences in ANA levels between the groups this is the single study that reported no difference in ANA between PCOS compared to control which can be attributed to differences in selection criteria of the patients.
The result of this study showed that DsDNA was signi icantly higher in PCOS compared to control (54.2 ± 20.3 vs. 24.0 ± 15.0 IU/ml) and that 28.0% of PCOS had elevated DsDNA compared to 2.0% in control, which is agreement with Makled et al (MAK-LED et al., 2015) (56.3 ± 25.7 vs. 26.0 ± 10.8 IU/ml for PCOS and control respectively) and in agreement with He ler-Frischmuth et al. (HEFLER-FRISCHMUTH et al., 2010) with both studies showing that DsDNA in signi icantly higher in PCOS compare to matched normal control, which in agreement with the result of the current study in which DsDNA had higher prediction of PCOS compared to ANA (AUC in ROC test was higher in DSDNA vs. ANA 0.901 vs. 0.809) indicating it consistency in elevation in PCOS and ANA had more variable elevation (MAKLED et al., 2015 ) (HEFLER-FRISCHMUTH et al., 2010 .
In this study serum ANA signi icantly correlated with FSH (r=0.341, p=0.016), with LH (r=0.351, p=0.012), and with TSH (r=0.398, p = 0.004); Makled et al. (MAKLED et al., 2015) agree with our indings only in cases TSH correlation with ANA which they found to be signi icant, while ANA correlation with FSH and LH appear to be not signi icant, He lerFrischmuth et al. (HEFLER-FRISCHMUTH et al., 2010) also found a signi icant correlation between TSH and ANA (p=0.03), in their study only TSH correlation with ANA which is more commonly elevated in immunological conditions while LH and FSH had lower immunogenicity compared to TSH.
In this study serum DsDNA also signi icantly correlated with FSH (r=0.331, p=0.019) with TSH (r=0.667, p <0.001) and not signi icantly with LH (r=0.252, p=0.077), Makled et al (MAKLED et al., 2015) disagree with our indings concerning the correlation between DsDNA with endocrine markers in which they found no such correlation to be found in (FSH, LH and TSH) while He ler-Frischmuth et al (HEFLER-FRISCHMUTH et al., 2010) agree with our indings except they also reported a signi icant correlation between DsDNA with LH in addition to signi icant correlation with FSH and TSH, since Ds-DNA is highly correlated with PCOS so it will be expected to highly correlated with the hormonal component of PCOS (TSH and FSH), other than that no clear mechanism can explain such observation.
The indings of this study in conjugation with previously reported studies (REIMAND et al., 2001 ) (MAKLED et al., 2015 ) (HEFLER-FRISCHMUTH et al., 2010 indicate a signi icant link between autoimmunity and PCOS, Glintborg et al. (GLINTBORG and ANDERSEN, 2010) reported an increased in lammatory response with overexpression in the immune mediator in PCOS patients, Fulghesuet at al (FULGHESU et al., 2011) show an association between monocytes in patients with insulin -resistance PCOS, and with interleukin 6 (which is in lammatory cytokine), other postulated the low levels of progesterone as a reason for immune overstimulation (PETRIKOVA et al., 2010) so these indings can indicate the elevation in ANA and DsDNA levels possibly caused by immune overstimulation and in lammation, Dehaghani et al. (DEHAGHANI et al., 2013) in their study of ovarian electrocauterization (to destroy parts of ovary that affected by PCOS) their observation of increase ANA levels after the procedure imply that manipulation in ovary tissues in women with PCOS provoke in lammatory response or increase release of in lammatory mediators (that either directly elevate ANA or DsDNA or precipitate their elevation) leading to autoimmunity, since one of the accepted theory of autoimmunity is tissue destruction (MACKAY et al., 2008) . No clear antibodies were found in previous studies directed to ovarian tissue but a status of an overall increased immune activation without speci ic antibody, which can be caused by different mechanisms that need to be clari ied (REIMAND et al., 2001) .
In this study we evaluated ANA and DsDNA as predictor of PCOS with found if ANA ≥5 had 84% sensitivity and 66% speci icity indicating that ANA had higher sensitivity compared to its speci icity and its better as a screening tool, while DsDNA with cut point ≥36 having 84% sensitivity and speci icity indicating it had similar clinical utility as con irmatory and screening diagnostic tool, Malked et al. (MAK-LED et al., 2015) in there study showed similar indings concerning the use of both DsDNA and ANA as diagnostic tool for PCOS; however thry found DsDNA had an optimal cut point of >74 and for ANA >9.8.
CONCLUSION
There is a clear relationship between immunological markers (ANA, DsDNA) with polycystic ovary syndrome in various components of the disease, dsDNA offer better ability than ANA as a predictor of PCOS, indicating that dsDNA can be used as non-invasive diagnostic tool for PCOS.
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